IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jay silberman who wrote (1288)	10/1/1997 11:19:00 AM
From: aknahow	of 1762

Jay, thanks for a most informative post. If anyone has contact with Mr. Hecht at M. Lynch I would greatly appreciate any info he has on the small royalty IDEC pays to XOMA for "intelectual property" involved in the development of Rituxan and licensed from XOMA. Congratulations on your intelligence in picking IDPH and hanging on, to all of the shareholders on this thread. With such a large sales estimate even a small royalty has more importance to XOMA than I though when sales were estimated at $400 million. The royalty is so small it will in no way detract from the importance of Rituxan for IDPH. Only want to get a fix on what the royalty actually is.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next